Eton Pharmaceuticals Inc. (ETON) Reports Q1 EPS of $0.19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Eton Pharmaceuticals Reports Record Revenue and Earnings
May 13, 2021 4:05 PM EDTFirst quarter 2021 revenue of $11.9 millionFirst quarter 2021 operating earnings of $5.4 million; EPS of $0.19Eton now has three commercial, revenue-generating products
DEER PARK, Ill., May 13, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2021 and provided an update on business progress.
We are proud to report record revenue and the first profitable quarter in Etons history, said Sean Brynjelsen, CEO of Eton Pharmaceuticals. We have... More
